AZN
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones -3.1% · nuevas posiciones netas -4.2% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 3.19M | $514.55M | n/a | −2 |
| Q2 2026 | 154 | +6 | 584.53M | $109.90B | +11 | −6 |
| Q1 2026 | 151 | +2 | 571.10M | $111.81B | +21 | −20 |
| Q4 2025 | 148 | 0 | 438.95M | $40.35B | +2 | −1 |
| Q3 2025 | 24 | 0 | 219.30M | $16.82B | +1 | −2 |
| Q2 2025 | 22 | -1 | 189.68M | $13.26B | n/a | −1 |
| Q1 2025 | 21 | 0 | 171.06M | $12.57B | n/a | n/a |
| Q4 2024 | 21 | +3 | 174.28M | $11.42B | +3 | n/a |
| Q3 2024 | 17 | -3 | 166.39M | $12.97B | n/a | −3 |
| Q2 2024 | 20 | n/a | 172.48M | $13.45B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 49.12M | -5.4% | $3.77B | 0.4% | ▼ Trim | 6 | SEC ↗ ×2 |
| 2 | PRIMECAP Management ✦ | 39.86M | -3.3% | $3.06B | 2.3% | ▼ Trim | 6 | SEC ↗ |
| 3 | Wellington Management ✦ | 32.30M | -5.9% | $2.48B | 0.4% | ▼ Trim | 6 | SEC ↗ ×7 |
| 4 | Fidelity (FMR) ✦ | 21.69M | +1.6% | $1.66B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 5 | Fisher Asset Management ✦ | 21.16M | +2.3% | $1.62B | 0.6% | ▲ Add | 6 | SEC ↗ |
| 6 | Goldman Sachs Group ✦ | 13.67M | n/a | $1.05B | 0.2% | n/c | 1 | SEC ↗ ×6 |
| 7 | Morgan Stanley ✦ | 13.45M | n/a | $1.03B | 0.1% | n/c | 1 | SEC ↗ ×15 |
| 8 | JPMorgan Chase ✦ | 9.65M | n/a | $740.21M | 0.0% | n/c | 1 | SEC ↗ ×34 |
| 9 | BlackRock ✦ (pasivo) | 5.80M | +5.8% | $445.31M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 10 | Citadel Advisors ✦ | 3.59M | +95.9% | $275.14M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 2.23M | +94.6% | $170.88M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | Capital World Investors ✦ | 1.09M | +612.2% | $83.50M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | State Street Global Advisors ✦ (pasivo) | 967.15K | +3.0% | $74.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 849.70K | -26.5% | $65.19M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Marshall Wace ✦ | 696.49K | -65.2% | $53.44M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 16 | Adage Capital Partners ✦ | 672.94K | +106.8% | $51.63M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 17 | Point72 Asset Management ✦ | 569.37K | -66.2% | $43.68M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 517.70K | -39.7% | $39.72M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (pasivo) | 503.47K | -0.3% | $38.63M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Bridgewater Associates ✦ | 462.86K | -25.4% | $35.51M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 231.63K | -87.8% | $17.77M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Dodge & Cox ✦ | 137.49K | 0.0% | $10.55M | 0.0% | Held | 6 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 84.78K | +57.2% | $6.50M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 24 | Gotham Asset Management ✦ | 2.74K | Nuevo | $209,983 | 0.0% | New | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Gotham Asset Management | $209,983 | 0.0% |
Posición cerrada
| Renaissance Technologies | $91.11M | era 0.1% |
| Norges Bank | $4.22M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1,307 tenedores, 729.50M acciones, $139.69B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Officer · See Remarks · 20 acc. @ 160.57 · $3,249
Ventas en mercado abierto (S)
Sin ventas en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología